Baricitinib granted breakthrough therapy designation (BTD) in US for treatment of alopecia areata

Alopecia areata is an autoimmune disease that can cause hair loss on scalp, face and other areas of the body. BTD was based on results of Phase II trial comparing baricitinib with placebo. It is now being investigated in phase III studies testing two doses (2 mg and 4 mg).


Biospace Inc.